A long-acting amylin analogue developed to enhance weight loss when combined with semaglutide.
Activates amylin receptors (AMY1–3) in the hypothalamus and area postrema, slowing gastric emptying and reducing meal-time food intake. Complements GLP-1 agonists by engaging separate satiety pathways, producing additive appetite suppression beyond either agent alone.
Developed by Novo Nordisk and studied in combination with semaglutide under the name CagriSema. Phase 3 trials show up to ~25% body weight reduction — substantially beyond semaglutide monotherapy.
Amylin is a hormone co-secreted with insulin from pancreatic beta cells. Cagrilintide mimics its actions but with a half-life engineered for once-weekly dosing through fatty acid conjugation.